Interleukin-19 in breast cancer

Ying Yin Chen, Chien Feng Li, Ching Hua Yeh, Ming Shi Chang, Chung-Hsi Hsing

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Inflammatory cytokines within the tumor microenvironment are linked to progression in breast cancer. Interleukin- (IL-) 19, part of the IL-10 family, contributes to a range of diseases and disorders, such as asthma, endotoxic shock, uremia, psoriasis, and rheumatoid arthritis. IL-19 is expressed in several types of tumor cells, especially in squamous cell carcinoma of the skin, tongue, esophagus, and lung and invasive duct carcinoma of the breast. In breast cancer, IL-19 expression is correlated with increased mitotic figures, advanced tumor stage, higher metastasis, and poor survival. The mechanisms of IL-19 in breast cancer have recently been explored both in vitro and in vivo. IL-19 has an autocrine effect in breast cancer cells. It directly promotes proliferation and migration and indirectly provides a microenvironment for tumor progression, which suggests that IL-19 is a prognostic marker in breast cancer and that antagonizing IL-19 may have therapeutic potential.

Original languageEnglish
Article number294320
JournalClinical and Developmental Immunology
Volume2013
DOIs
Publication statusPublished - 2013

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Fingerprint Dive into the research topics of 'Interleukin-19 in breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Chen, Y. Y., Li, C. F., Yeh, C. H., Chang, M. S., & Hsing, C-H. (2013). Interleukin-19 in breast cancer. Clinical and Developmental Immunology, 2013, [294320]. https://doi.org/10.1155/2013/294320